Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-24 @ 10:59 PM
Ignite Modification Date: 2025-12-25 @ 8:28 PM
NCT ID: NCT00790569
Description: None
Frequency Threshold: 0
Time Frame: None
Study: NCT00790569
Study Brief: Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
Arm I Patients receive oral varenicline once daily on days 1-3 and twice daily thereafter for a total of 6 months or when a comfortable level of smoking abstinence is reached. varenicline: Given orally None None 4 137 0 137 View
Arm II Patients receive oral varenicline placebo once daily on days 1-3 and twice daily thereafter for a total of 6 months or when a comfortable level of smoking abstinence is reached. placebo: Given orally None None 2 45 0 45 View
Arm III Patients receive a nicotine patch, with doses tapering over time for a total of 26 weeks. Patients also receive nicotine gum to quell breakthrough urges. Patients may stop treatment when a comfortable level of smoking abstinence is reached. nicotine: Given transdermally and orally None None 2 133 0 133 View
Serious Events(If Any):

Serious Events

Term Type Organ System Vocab View
Neurobehavioral Adverse Effects None Psychiatric disorders None View
Neurobehavioral Adverse Events None Psychiatric disorders None View
Participant Death None General disorders None View
Heart Attack None Cardiac disorders None View
Skin Rash None Skin and subcutaneous tissue disorders None View
Other Events(If Any):